ClinicalTrials.gg

Program

mufemilast

Also written as “Hemay005”, “Hemay005 tablet” and “Hemay005 tablets”.

Its studies are mostly in Psoriasis · Colitis, Ulcerative · Pulmonary Disease, Chronic Obstructive · Behcet Syndrome · Dermatitis, Atopic, led by 4 companies.

Furthest: phase 3, since Nov 17, 202320 company-led studies, 5 open or runningNext primary completion: Dec 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ganzhou Hemay Pharmaceutical115 open or runningphase 3since Nov 17, 2023Jun 15, 2022Dec 30, 2026phase 2 · NCT05486104
Tianjin Hemay Pharmaceutical50 open or runningphase 3since Apr 1, 2021Mar 20, 2019none ahead
Tianjin Hemay Bio-Tech30 open or runningphase 1since Dec 22, 2016Dec 22, 2016none ahead
Anhui Hemay Pharmaceutical10 open or runningphase 1since Mar 18, 2025Mar 18, 2025none ahead

Also a collaborator on its studies: hemay-pharmaceutical-pty-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Dec 22, 2016.

  1. Oct 19, 2020Phase 2 study in Behcet SyndromeTianjin Hemay Pharmaceutical · NCT04609397 · 89 enrolled · China
  2. Apr 1, 2021Phase 3 study in PsoriasisTianjin Hemay Pharmaceutical · NCT04839328 · 306 enrolled · China
  3. Apr 7, 2021Phase 1 study in PsoriasisTianjin Hemay Pharmaceutical · NCT04837235 · 12 enrolled · China
  4. May 30, 2022Phase 2 study in Active Ankylosing SpondylitisTianjin Hemay Pharmaceutical · NCT05407246 · 90 enrolled · China
  5. Jun 15, 2022Ganzhou Hemay Pharmaceutical's first study: phase 1 study in Health VolunteerNew to Ganzhou Hemay PharmaceuticalGanzhou Hemay Pharmaceutical · NCT05468645 · 6 enrolled · China
  6. Aug 1, 2022Phase 2 study in Moderate to Severe Ulcerative ColitisGanzhou Hemay Pharmaceutical · NCT05486104 · 92 enrolled · China
  7. Mar 3, 2023Phase 2 study in Dermatitis, AtopicGanzhou Hemay Pharmaceutical · NCT05769946 · 79 enrolled · China
  8. Apr 5, 2023Phase 1 study in HealthyGanzhou Hemay Pharmaceutical · NCT05941247 · 12 enrolled · Australia
  9. Nov 17, 2023Phase 3 study in Behcet SyndromeGanzhou Hemay Pharmaceutical · NCT06145893 · 162 planned · China
  10. Apr 9, 20242 phase 1 studies in PsoriasisGanzhou Hemay Pharmaceutical · NCT06380153, NCT06376474
  11. Sep 20, 20242 phase 1 studies in PsoriasisGanzhou Hemay Pharmaceutical · NCT06610903, NCT06610890
  12. Mar 18, 2025Anhui Hemay Pharmaceutical's first study: phase 1 study in Pulmonary Disease, Chronic ObstructiveNew to Anhui Hemay PharmaceuticalAnhui Hemay Pharmaceutical · NCT06908642 · 468 enrolled · China
  13. Dec 18, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveGanzhou Hemay Pharmaceutical · NCT07314242 · 120 planned · China
  14. Jun 3, 2026Phase 3 study in Colitis, UlcerativeGanzhou Hemay Pharmaceutical · NCT07650942 · 360 planned · China

Ahead

  1. Dec 30, 2026Primary completion: phase 2 study in Moderate to Severe Ulcerative ColitisGanzhou Hemay Pharmaceutical · NCT05486104
  2. Dec 31, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveGanzhou Hemay Pharmaceutical · NCT07314242
  3. May 2028Primary completion: phase 3 study in Colitis, UlcerativeGanzhou Hemay Pharmaceutical · NCT07650942

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07650942Colitis, Ulcerative · China3Not yet recruitingGanzhou Hemay PharmaceuticalMay 2028360
NCT07314242Pulmonary Disease, Chronic Obstructive · China2Not yet recruitingGanzhou Hemay PharmaceuticalDec 31, 2027120
NCT06908642Pulmonary Disease, Chronic Obstructive · China1CompletedAnhui Hemay PharmaceuticalJun 3, 2025468
NCT06610903Psoriasis · China1CompletedGanzhou Hemay PharmaceuticalSep 30, 202428
NCT06610890Psoriasis · China1CompletedGanzhou Hemay PharmaceuticalJan 20, 202520
NCT06380153Psoriasis · China1CompletedGanzhou Hemay PharmaceuticalApr 16, 202526
NCT06376474Psoriasis · China1RecruitingGanzhou Hemay PharmaceuticalDec 10, 202524
NCT06145893Behcet Syndrome · China3RecruitingGanzhou Hemay PharmaceuticalMay 30, 2026162
NCT05941247Healthy · Australia1CompletedGanzhou Hemay PharmaceuticalAug 8, 202312
NCT05769946Dermatitis, Atopic · China2CompletedGanzhou Hemay PharmaceuticalJan 24, 202479
NCT05486104Moderate to Severe Ulcerative Colitis · China2Active, not recruitingGanzhou Hemay PharmaceuticalDec 30, 202692
NCT05468645Health Volunteer · China1CompletedGanzhou Hemay PharmaceuticalSep 1, 20226
NCT05407246Active Ankylosing Spondylitis · China2CompletedTianjin Hemay PharmaceuticalAug 18, 202390
NCT04837235Psoriasis · China1CompletedTianjin Hemay PharmaceuticalAug 1, 202112
NCT04839328Psoriasis · China3CompletedTianjin Hemay PharmaceuticalOct 25, 2022306
NCT04609397Behcet Syndrome · China2TerminatedTianjin Hemay PharmaceuticalApr 30, 202289
NCT04102241Psoriasis · China2CompletedTianjin Hemay PharmaceuticalOct 12, 2020216
NCT03577626Psoriasis1UNKNOWNTianjin Hemay Bio-TechNov 10, 201812
NCT03570346Psoriasis · China1UNKNOWNTianjin Hemay Bio-TechOct 20, 201824
NCT03007810Psoriasis · China1CompletedTianjin Hemay Bio-TechJun 201868

How it is read

Names in the registry

  • “Hemay005”, 15 entries
  • “Hemay005 tablet”, 3 entries
  • “Hemay005 tablets”, 2 entries
  • “Hemay005 60 mg”, 1 entry
  • “[14C]Hemay005”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.